Prospective feasibility pilot study evaluating the value of [68Ga]Ga-PENTIXAFOR PET-CT in patients with locally advanced or metastatic Small Cell Lung Cancer (SCLC) at diagnosis and disease progression (PASSIFLORE)

2024-514057-30-00 Protocol ICO-2023-16 Human pharmacology (Phase I) - Other Authorised, recruitment pending

Status Authorised, recruitment pending · 1 EU/EEA countries · 3 sites · Protocol ICO-2023-16

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Authorised, recruitment pending
Participants planned 15
Countries 1
Sites 3

cell lung carcinoma

Key facts

Sponsor
Institut De Cancerologie De L Ouest
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Decision date (initial)
2025-05-06
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

External identifiers

EU CT number
2024-514057-30-00
ClinicalTrials.gov
NCT07007325

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

cell lung carcinoma

VersionLevelCodeTermSystem organ class
27.0 PT 10059514 Small cell lung cancer metastatic 100000004864
21.1 PT 10041069 Small cell lung cancer limited stage 100000004864

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Institut De Cancerologie De L Ouest

Sponsor organisation
Institut De Cancerologie De L Ouest
Address
15 Rue Andre Boquel
City
Angers
Postcode
49100
Country
France

Scientific contact point

Organisation
Institut De Cancerologie De L Ouest
Contact name
LACOMBE Marie

Public contact point

Organisation
Institut De Cancerologie De L Ouest
Contact name
LACOMBE Marie

Locations

1 EU/EEA country · 3 investigational sites

By country

CountryMS statusPlanned subjectsSites
France Authorised, recruitment pending 15 3
Rest of world 0

Investigational sites

France

3 sites · Authorised, recruitment pending
Centre Hospitalier Regional D'Angers
Nuclear Medicine, 4 Rue Larrey, 49100, Angers
Institut De Cancerologie De L Ouest
Nuclear Medicine, Boulevard Jacques Monod, 44805, Saint-Herblain Cedex
Institut De Cancerologie De L Ouest
Nuclear Medicine, 15 Rue Andre Boquel, 49100, Angers

Application history

3 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-01-31 France Acceptable
2025-05-06
2025-05-06
2 SUBSTANTIAL MODIFICATION SM-1 2025-09-15 France Acceptable
2025-10-30
2025-10-30
3 SUBSTANTIAL MODIFICATION SM-2 2026-02-10 France Acceptable
2026-03-05
2026-03-12